Antiviral activities of nucleotide heterodimers against human immunodeficiency virus type 1 in vitro. 1996

K Ijichi, and M Fujiwara, and K Mori, and M Morozumi, and H Machida, and S Shigeta, and K Konno, and T Yokota, and M Baba
Rational Drug Design Laboratories, Fukushima, Japan.

Nucleotide heterodimers were synthesized and examined for their inhibitory effects on the replication of human immunodeficiency virus type 1 (HIV-1), including HIV-1 reverse transcriptase (RT) inhibitor-resistant mutants. 3'-Azido-3'-deoxythymidilyl-(5')-phospho-(5')-6-[(3', 5'-dimethylphenyl)thio]-5-ethyl-1-[(2-hydroxyethoxy)methyl]uracil (AZT-P-E-HEPU-dM) and 3'-azido-3'-deoxythymidilyl-(5')-phospho-(5')-2', 3'-dideoxyinosine (AZT-P-ddI) proved to be highly potent and selective inhibitors of HIV-1 (IIIB strain) in MT-4 cells. The mechanism of inhibition by these heterodimers may be attributed to their degradation and the formation of each constituent. AZT-P-E-HEPU-dM was also markedly inhibitory to an AZT-resistant mutant (HIV-1-IIIB/AZT) and an E-HEPU-dM-resistant mutant (HIV-1-IIIB-R). However, AZT-P-ddI was found to have a less inhibitory effect on HIV-1-IIIB/AZT than on HIV-1-IIIB. The heterodimers of (5',5') AZT and ribavirin (AZT-P-Ribavirin) and (5',5') ddI and ribavirin (ddI-P-Ribavirin) were also synthesized: AZT-P-Ribavirin inhibited HIV-1 replication, but ddI-P-Ribarvirin did not.

UI MeSH Term Description Entries
D002461 Cell Line, Transformed Eukaryotic cell line obtained in a quiescent or stationary phase which undergoes conversion to a state of unregulated growth in culture, resembling an in vitro tumor. It occurs spontaneously or through interaction with viruses, oncogenes, radiation, or drugs/chemicals. Transformed Cell Line,Cell Lines, Transformed,Transformed Cell Lines
D003588 Cytopathogenic Effect, Viral Visible morphologic changes in cells infected with viruses. It includes shutdown of cellular RNA and protein synthesis, cell fusion, release of lysosomal enzymes, changes in cell membrane permeability, diffuse changes in intracellular structures, presence of viral inclusion bodies, and chromosomal aberrations. It excludes malignant transformation, which is CELL TRANSFORMATION, VIRAL. Viral cytopathogenic effects provide a valuable method for identifying and classifying the infecting viruses. Cytopathic Effect, Viral,Viral Cytopathogenic Effect,Cytopathic Effects, Viral,Cytopathogenic Effects, Viral,Effect, Viral Cytopathic,Effect, Viral Cytopathogenic,Effects, Viral Cytopathic,Effects, Viral Cytopathogenic,Viral Cytopathic Effect,Viral Cytopathic Effects,Viral Cytopathogenic Effects
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D012254 Ribavirin A nucleoside antimetabolite antiviral agent that blocks nucleic acid synthesis and is used against both RNA and DNA viruses. Ribovirin,Tribavirin,ICN-1229,Rebetol,Ribamide,Ribamidil,Ribamidyl,Ribasphere,Vilona,Viramide,Virazide,Virazole,ICN 1229,ICN1229
D014498 Uracil One of four nucleotide bases in the nucleic acid RNA.
D015215 Zidovudine A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by an azido group. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. The compound is a potent inhibitor of HIV replication, acting as a chain-terminator of viral DNA during reverse transcription. It improves immunologic function, partially reverses the HIV-induced neurological dysfunction, and improves certain other clinical abnormalities associated with AIDS. Its principal toxic effect is dose-dependent suppression of bone marrow, resulting in anemia and leukopenia. AZT (Antiviral),Azidothymidine,3'-Azido-2',3'-Dideoxythymidine,3'-Azido-3'-deoxythymidine,AZT Antiviral,AZT, Antiviral,BW A509U,BWA-509U,Retrovir,3' Azido 2',3' Dideoxythymidine,3' Azido 3' deoxythymidine,Antiviral AZT,BWA 509U,BWA509U
D015497 HIV-1 The type species of LENTIVIRUS and the etiologic agent of AIDS. It is characterized by its cytopathic effect and affinity for the T4-lymphocyte. Human immunodeficiency virus 1,HIV-I,Human Immunodeficiency Virus Type 1,Immunodeficiency Virus Type 1, Human
D016049 Didanosine A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by a hydrogen. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. Didanosine is a potent inhibitor of HIV replication, acting as a chain-terminator of viral DNA by binding to reverse transcriptase; ddI is then metabolized to dideoxyadenosine triphosphate, its putative active metabolite. 2',3'-Dideoxyinosine,Dideoxyinosine,ddI (Antiviral),NSC-612049,Videx,2',3' Dideoxyinosine,NSC 612049,NSC612049
D019380 Anti-HIV Agents Agents used to treat AIDS and/or stop the spread of the HIV infection. These do not include drugs used to treat symptoms or opportunistic infections associated with AIDS. AIDS Drug,AIDS Drugs,Anti-AIDS Agents,Anti-AIDS Drug,Anti-HIV Agent,Anti-HIV Drug,Anti-AIDS Drugs,Anti-HIV Drugs,Agent, Anti-HIV,Agents, Anti-AIDS,Agents, Anti-HIV,Anti AIDS Agents,Anti AIDS Drug,Anti AIDS Drugs,Anti HIV Agent,Anti HIV Agents,Anti HIV Drug,Anti HIV Drugs,Drug, AIDS,Drug, Anti-AIDS,Drug, Anti-HIV,Drugs, AIDS,Drugs, Anti-AIDS,Drugs, Anti-HIV

Related Publications

K Ijichi, and M Fujiwara, and K Mori, and M Morozumi, and H Machida, and S Shigeta, and K Konno, and T Yokota, and M Baba
January 1991, Chemical & pharmaceutical bulletin,
K Ijichi, and M Fujiwara, and K Mori, and M Morozumi, and H Machida, and S Shigeta, and K Konno, and T Yokota, and M Baba
April 1995, AIDS research and human retroviruses,
K Ijichi, and M Fujiwara, and K Mori, and M Morozumi, and H Machida, and S Shigeta, and K Konno, and T Yokota, and M Baba
June 1991, Chemical & pharmaceutical bulletin,
K Ijichi, and M Fujiwara, and K Mori, and M Morozumi, and H Machida, and S Shigeta, and K Konno, and T Yokota, and M Baba
January 1996, Phytomedicine : international journal of phytotherapy and phytopharmacology,
K Ijichi, and M Fujiwara, and K Mori, and M Morozumi, and H Machida, and S Shigeta, and K Konno, and T Yokota, and M Baba
March 2001, Bioscience, biotechnology, and biochemistry,
K Ijichi, and M Fujiwara, and K Mori, and M Morozumi, and H Machida, and S Shigeta, and K Konno, and T Yokota, and M Baba
January 2002, Phytomedicine : international journal of phytotherapy and phytopharmacology,
K Ijichi, and M Fujiwara, and K Mori, and M Morozumi, and H Machida, and S Shigeta, and K Konno, and T Yokota, and M Baba
November 1997, AIDS research and human retroviruses,
K Ijichi, and M Fujiwara, and K Mori, and M Morozumi, and H Machida, and S Shigeta, and K Konno, and T Yokota, and M Baba
July 2004, Biochemical and biophysical research communications,
K Ijichi, and M Fujiwara, and K Mori, and M Morozumi, and H Machida, and S Shigeta, and K Konno, and T Yokota, and M Baba
August 2005, The Journal of general virology,
K Ijichi, and M Fujiwara, and K Mori, and M Morozumi, and H Machida, and S Shigeta, and K Konno, and T Yokota, and M Baba
June 2002, Antiviral research,
Copied contents to your clipboard!